Physician profile
Adam L Peyton
NPI 1558565598
$985,177.34
in general payments reported to CMS, 2019-2025
26 companies · $241K in 2025
The $241K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193K · 2020: $88K · 2021: $77K · 2022: $134K · 2023: $123K · 2024: $129K · 2025: $241K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $352K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $83K · Travel and Lodging: $35K · Food and Beverage: $13K · Consulting Fee: $7,081 · Honoraria: $3,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $351,600.56 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $82,755.00 |
| Travel and Lodging | $35,453.69 |
| Food and Beverage | $13,197.08 |
| Consulting Fee | $7,081.25 |
| Honoraria | $3,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $325,318.76 | 2019-2025 | Livdelzi, Epclusa, Vemlidy |
| Abbvie INC. | $175,945.53 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $171,383.33 | 2019-2024 | Ocaliva |
| Madrigal Pharmaceuticals | $113,552.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108,143.24 | 2019-2025 | Xifaxan, Plenvu |
| Ipsen Biopharmaceuticals, INC | $28,942.07 | 2024-2025 | Iqirvo, Bylvay |
| Mallinckrodt Hospital Products INC. | $23,698.97 | 2024-2025 | Terlivaz |
| Novo Nordisk INC | $23,559.15 | 2022-2025 | Wegovy |
| Shionogi INC | $7,270.86 | 2019-2020 | |
| Dova Pharmaceuticals | $6,085.21 | 2019-2020 | |
| Janssen Biotech, INC. | $274.74 | 2023-2025 | Stelara, Tremfya |
| Janssen Scientific Affairs, LLC | $249.96 | 2022 | |
| Ferring Pharmaceuticals INC. | $129.01 | 2019-2023 | Clenpiq |
| Intra-Sana Laboratories | $127.17 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Phathom Pharmaceuticals, INC. | $110.01 | 2024 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $105.32 | 2023 | |
| Orphalan INC | $95.80 | 2024 | Cuvrior |
| Boston Scientific Corporation | $51.22 | 2019 | |
| Pfizer INC. | $29.65 | 2019 | |
| Allergan, INC. | $27.50 | 2019 | |
| Glaxosmithkline, LLC. | $25.91 | 2023 | |
| Celgene Corporation | $21.46 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.56 | 2019 | |
| Covidien Lp | $13.63 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Peyton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.